GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Merdury Biopharmaceutical 6932.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

5.23

+1.75%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

—

FY2019FY2025

Net income

−TWD 67.2m

FY2019FY2025

Free cash flow

−TWD 58.1m

FY2019FY2025

Shareholders' equity

TWD 219.7m

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue—TWD 5.0mTWD 1.0mTWD 2.7m———
Research and developmentTWD 44.2mTWD 32.7mTWD 21.4mTWD 15.4mTWD 2.8m——
Operating income−TWD 68.5m−TWD 54.0m−TWD 43.1m−TWD 30.9m−TWD 5.3m−TWD 210,000−TWD 199,000
Net income−TWD 67.2m−TWD 50.6m−TWD 43.8m−TWD 31.3m−TWD 5.3m−TWD 210,000−TWD 199,000
Diluted earnings per share-0.15-0.11-0.11-0.08-0.01-0.00—

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assetsTWD 278.4mTWD 353.2mTWD 438.1mTWD 229.9mTWD 13.4mTWD 97,000TWD 157,000
Cash and short-term investments——TWD 329.1mTWD 140.6mTWD 2.6mTWD 86,000TWD 153,000
Total liabilitiesTWD 58.7mTWD 62.9mTWD 49.7mTWD 49.6mTWD 2.9mTWD 306,000TWD 156,000
DebtTWD 38.1mTWD 40.4mTWD 42.3mTWD 43.4mTWD 2.0mTWD 300,000TWD 150,000
Shareholders' equityTWD 219.7mTWD 290.3mTWD 388.4mTWD 180.3mTWD 10.5m−TWD 209,000TWD 1,000
Shares outstanding458m458m416m401m458m458m406m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−TWD 50.8m−TWD 34.7m−TWD 42.1m−TWD 25.8m−TWD 4.8m−TWD 217,000−TWD 197,000
Capital spending−TWD 7.3m−TWD 11.1m−TWD 13.6m−TWD 68.7m−TWD 7.5m——
Free cash flow−TWD 58.1m−TWD 45.8m−TWD 55.7m−TWD 94.5m−TWD 12.3m−TWD 217,000−TWD 197,000

Latest quarters

By quarter end

Jun 2025Dec 2024Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023Mar 2023
Revenue—TWD 246,000TWD 2.4mTWD 2.4mTWD 516,499TWD 516,499——
Operating income−TWD 39.4m−TWD 33.6m−TWD 10.2m−TWD 10.2m−TWD 13.2m−TWD 13.2m−TWD 9.6m−TWD 9.6m
Net income−TWD 38.3m−TWD 32.3m−TWD 9.2m−TWD 9.2m−TWD 12.6m−TWD 12.6m−TWD 9.4m−TWD 9.4m
Diluted earnings per share-0.09-0.08-0.02-0.02-0.03-0.03-0.02-0.02
Cash from operations−TWD 26.0m−TWD 25.0m−TWD 4.0m−TWD 4.0m−TWD 9.0m−TWD 9.0m−TWD 11.0m−TWD 11.0m
Capital spending−TWD 3.0m−TWD 5.0m−TWD 2.0m−TWD 2.0m−TWD 5.0m−TWD 5.0m−TWD 1.0m−TWD 1.0m
Free cash flow−TWD 29.0m−TWD 30.0m−TWD 6.0m−TWD 6.0m−TWD 14.0m−TWD 14.0m−TWD 12.0m−TWD 12.0m
Total assetsTWD 317.0mTWD 353.2mTWD 378.8mTWD 378.8mTWD 438.1mTWD 438.1mTWD 459.2mTWD 459.2m
Cash and short-term investments——TWD 264.9mTWD 264.9mTWD 329.1mTWD 329.1mTWD 356.6mTWD 356.6m
DebtTWD 39.2mTWD 40.4mTWD 41.4m—TWD 681,000—TWD 1.1m—
Shareholders' equityTWD 252.3mTWD 290.3mTWD 323.9mTWD 323.9mTWD 388.4mTWD 388.4mTWD 412.5mTWD 412.5m

Financial ratios

Data as of 22 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin—-1002.0%-4172.8%-1151.1%——
Net margin—-1018.9%-4241.6%-1166.0%——
Return on equity-30.6%-17.4%-11.3%-17.3%-50.8%100.5%
Return on assets-24.2%-14.3%-10.0%-13.6%-39.7%-216.5%
Free cash flow yield—-0.9%-1.2%1.8%——
Revenue growth—380.4%-61.5%———
Earnings growth33.0%15.4%40.2%488.6%2428.1%—
Current ratio8.84x12.63x42.21x20.15x2.30x0.32x
Debt to equity0.17x0.14x0.11x0.24x0.08x-1.44x
Equity ratio78.9%82.2%88.7%78.4%78.1%-215.5%
Interest coverage-73.80x-62.08x-60.63x-77.13x-481.64x—
R&D as a share of sales—658.0%2068.5%575.0%——
Buybacks as a share of market value—-10.0%-3.6%———

Growth per year

Compound annual rate

3 years5 years10 years
Operating income30.5%218.2%—
Net income29.1%217.0%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings-56.6-118.1-175.7-127.7

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.